Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC

EGFR mutant mNSCLC: Single agent or in combination?

Date

22 Nov 2019

Session

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC

Topics

Cytotoxic Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Fabrice Barlesi

Authors

F. Barlesi

Author affiliations

  • Aix-Marseille University - Faculté de Médecine Nord, 13015 - Marseille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.